Arrowstreet Capital Limited Partnership Has $58.79 Million Stake in AbbVie Inc. $ABBV

Arrowstreet Capital Limited Partnership trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 12.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 316,713 shares of the company’s stock after selling 45,182 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in AbbVie were worth $58,788,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after buying an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after buying an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after buying an additional 1,517,222 shares during the period. Norges Bank acquired a new position in AbbVie in the 2nd quarter valued at about $4,288,200,000. Finally, Northern Trust Corp raised its holdings in AbbVie by 0.9% in the 1st quarter. Northern Trust Corp now owns 22,013,920 shares of the company’s stock valued at $4,612,357,000 after acquiring an additional 189,294 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE ABBV opened at $228.68 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a market capitalization of $404.17 billion, a price-to-earnings ratio of 173.24, a P/E/G ratio of 1.24 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The firm’s 50 day simple moving average is $228.19 and its 200 day simple moving average is $207.90.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the business posted $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is presently 496.97%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ABBV. Scotiabank assumed coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. HSBC set a $225.00 price target on AbbVie in a research note on Thursday, October 2nd. Hsbc Global Res cut AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Finally, Guggenheim upped their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.